Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
BörsenkürzelGRAL
Name des UnternehmensGrail Inc
IPO-datumJun 12, 2024
CEORagusa (Robert)
Anzahl der mitarbeiter1000
WertpapierartOrdinary Share
GeschäftsjahresendeJun 12
Addresse1525 O'brien Drive
StadtMENLO PARK
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl94025
Telefon18336942553
Websitehttps://grail.com/
BörsenkürzelGRAL
IPO-datumJun 12, 2024
CEORagusa (Robert)
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten